7/3/2013

Array BioPharma earned a $5 million milestone payment from Novartis for initiating a late-stage trial of experimental drug MEK162 in low-grade serous ovarian cancer patients. Novartis also plans to conduct late-stage studies to assess the efficacy of MEK162 in melanoma patients with NRAS and BRAF mutations.

Related Summaries